A Phase 4 interventional study of Epoetin alfa in Renal Insufficiency, Chronic, Anemia and Renal Dialysis, sponsored by Amgen. Completed at 37 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-19.
Sponsored by Amgen · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic — 1 open to participants now, 1 under way, none of them phase 3. Epoetin Alfa · Renal Insufficiency, Chronic.
Among the 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic, this one is the 12th largest by enrollment, is one of 2 that started in 2015, is one of 7 in phase 4, and was the 21st registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →1 of the 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic is open now, in 1 country. Recruiting first, the newest first:
Services Hospital, Lahore · Sites in Pakistan
Ages 18–65
By country, each count listing its studies:
Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 435 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2015.
This study's enrollment of 216 is above the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 157 across the 25 interventional studies. Of the 23 that completed or were terminated, 14 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 25 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
54 studies in Renal Insufficiency, Chronic by Amgen: 2 open now, 2 under way, 2 of them phase 3. Of 51 finished, 28 (55%) have results posted.
Among the 54 studies in Renal Insufficiency, Chronic by Amgen, this one is the 21st largest by enrollment of the 44 interventional ones that give a count, is one of 2 that started in 2015, is one of 11 in phase 4, and was the 48th registered.
Amgen’s Renal Insufficiency, Chronic studies by the year they started, since 2002.
1 of the studies testing Epoetin Alfa in Renal Insufficiency, Chronic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07755683Services Hospital, LahoreEffect of Daprodustat and Epoetin Alpha on Anemia in Patients Not Undergoing Dialysis | 2027-02-28 |
Add it to your calendar (.ics) → With an account.
Among the 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 54 in Renal Insufficiency, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare two different dosing methods of epoetin alfa and their effectiveness in maintaining hemoglobin levels between 10.0 to 11.0 g/dL in in patients with chronic kidney disease (CKD) receiving hemodialysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Occurrence of any of the following within 8 weeks prior to randomization:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received epoetin alfa administered intravenously three times a week during hemodialysis for up to 37 weeks. For the first two weeks the dose of epoetin alfa was based on the dose at the time of screening. Beginning at week 3 dose changes may have occurred every 2 weeks according to the alternative dosing algorithm, where smaller, frequent dose adjustments were permitted based on six hemoglobin categories.
Drug: Epoetin alfa
Participants received epoetin alfa administered intravenously three times a week during hemodialysis for 37 weeks. For the first two weeks the dose of epoetin alfa was based on the dose at the time of screening. Beginning at week 3 dose decreases were permitted every 2 weeks and beginning at week 5 dose increases could only occur ≥ 4 weeks from the last dose increase, according to the United States package insert (USPI) dosing algorithm which includes four categories of hemoglobin levels.
Drug: Epoetin alfa
Administered intravenously (IV) three times a week (TIW) by appropriately trained healthcare professionals during hemodialysis.
Also known as: Epogen
Percentage of Hemoglobin Measurements Within 10 to 11 g/dL During the Evaluation Period
Hemoglobin was measured every 2 weeks during the evaluation period. The percentage of these measurements that were within the range of 10-11 g/dL was calculated for each participant.
Time frame: The evaluation period (weeks 13-37)
Hemoglobin Concentration at Each Visit
Time frame: Baseline (screening visit) and weeks 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, and 37
Percentage of Participants With Transfusion Events Overall and During Each Study Period
The percentage of participants who received red blood cell (RBC) transfusions during the study and during each study period.
Time frame: Overall Study: Study week 1 to week 41; Titration Period: Study week 1 to week 12; Evaluation Period: Study week 13 to week 37; Safety Follow-up Period: Study week 38 to week 41
Hemoglobin Rate of Change at Each Visit
Hemoglobin rate of change (ROC) was calculated for each visit using the following formula: ROC = (current visit hemoglobin value - previous visit hemoglobin value) / number of days between each visit \* 14. A positive value indicates a rate of rise and a negative value indicates a rate of decline.
Time frame: Baseline (screening visit) and weeks 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, and 37
Hemoglobin Intra-subject Variability
Intra-subject variability was defined for each participant as the standard deviation (SD) of all of the hemoglobin concentrations during the evaluation period for the participant. The mean intra-subject SD for all participants is the sum of the intra-subject SDs divided by the total number of participants evaluated.
Time frame: The evaluation period (weeks 13 to 37)
Percentage of Participants With Hemoglobin Excursions at Each Visit
An excursion is identified as an event when a hemoglobin concentration fell below or exceeded the pre-specified thresholds of: - \< 9.0 g/dL, or - \> 11.0 g/dL, or - \> 12.0 g/dL. The percentage of participants with any excursions and excursions in each subcategory at each time point and overall during the study are reported.
Time frame: Baseline (screening visit) and weeks 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, and 37
Weekly Epoetin Alfa Dose at Each Visit
Time frame: Weeks 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35
Number of RBC Units Transfused Overall and During Each Study Period
The number of red blood cell (RBC) units transfused during the study and during each study period.
Time frame: Overall Study: Study week 1 to week 41; Titration Period: Study week 1 to week 12; Evaluation Period: Study week 13 to week 37; Safety Follow-up Period: Study week 38 to week 41
This study was conducted at 31 centers in the United States. Participants were enrolled from 01 April 2015 to 17 August 2015.
| Milestone | Epoetin Alfa Alternative Titration | Epoetin Alfa USPI Titration |
|---|---|---|
| Started | 108 | 108 |
| Received treatment | 104 | 107 |
| Completed | 85 | 90 |
| Not completed | 23 | 18 |
| Withdrew: Withdrawal by subject | 12 | 4 |
| Withdrew: Decision by sponsor | 1 | 1 |
| Withdrew: Lost to follow-up | 2 | 5 |
| Withdrew: Death | 4 | 7 |
| Withdrew: Did not receive study treatment | 4 | 1 |
Hemoglobin was measured every 2 weeks during the evaluation period. The percentage of these measurements that were within the range of 10-11 g/dL was calculated for each participant.
| percentage of hemoglobin measurements | Epoetin Alfa Alternative Titration | Epoetin Alfa USPI Titration |
|---|---|---|
| Percentage of Hemoglobin Measurements Within 10 to 11 g/dL During the Evaluation Period | 46.41 ± 2.39 | 46.02 ± 2.56 |
| g/dL | Epoetin Alfa Alternative Titration | Epoetin Alfa USPI Titration |
|---|---|---|
| Baseline (n = 89, 100) | 10.15 ± 0.66 | 10.04 ± 0.81 |
| Week 3 (n = 89, 100) | 10.54 ± 0.88 | 10.34 ± 0.97 |
| Week 5 (n = 89, 99) | 10.66 ± 0.93 | 10.51 ± 1.04 |
| Week 7 (n = 88, 97) | 10.45 ± 1.02 | 10.28 ± 1.07 |
| Week 9 (n = 89, 100) | 10.32 ± 1.16 | 9.97 ± 0.87 |
| Week 11 (n = 88, 99) | 10.33 ± 1.05 | 10.15 ± 0.88 |
| Week 13 (n = 89, 100) | 10.28 ± 1.04 | 9.99 ± 0.91 |
| Week 15 (n = 89, 100) | 10.46 ± 1.38 | 9.98 ± 0.93 |
| Week 17 (n = 89, 100) | 10.20 ± 1.05 | 10.01 ± 1.22 |
| Week 19 (n = 89, 100) | 10.37 ± 1.14 | 9.94 ± 0.87 |
| Week 21 (n = 87, 99) | 10.33 ± 1.01 | 9.92 ± 0.81 |
| Week 23 (n = 88, 98) | 10.46 ± 1.05 | 10.03 ± 0.86 |
| Week 25 (n = 87, 98) | 10.56 ± 1.00 | 9.94 ± 0.97 |
| Week 27 (n = 88, 94) | 10.32 ± 1.10 | 9.97 ± 0.86 |
| Week 29 (n =89, 92) | 10.34 ± 1.01 | 10.02 ± 1.07 |
| Week 31 (n = 85, 89) | 10.34 ± 0.95 | 9.96 ± 1.07 |
| Week 33 (n = 86, 90) | 10.18 ± 1.00 | 10.05 ± 0.92 |
| Week 35 (n = 87, 88) | 10.12 ± 1.23 | 9.94 ± 0.90 |
| Week 37 (n = 87, 93) | 10.10 ± 1.11 | 9.86 ± 0.85 |
The percentage of participants who received red blood cell (RBC) transfusions during the study and during each study period.
| percentage of participants | Epoetin Alfa Alternative Titration | Epoetin Alfa USPI Titration |
|---|---|---|
| Overall (n = 89, 100) | 6.7 | 12.0 |
| Titration Period (n = 89, 100) | 2.2 | 1.0 |
| Evaluation Period (n = 89, 100) | 5.6 | 10.0 |
| Safety Follow-up Period (n = 83, 90) | 1.2 | 1.1 |
Hemoglobin rate of change (ROC) was calculated for each visit using the following formula: ROC = (current visit hemoglobin value - previous visit hemoglobin value) / number of days between each visit \* 14. A positive value indicates a rate of rise and a negative value indicates a rate of decline.
| g/dL/2 weeks | Epoetin Alfa Alternative Titration | Epoetin Alfa USPI Titration |
|---|---|---|
| Week 3 (n = 89, 100) | 0.36 ± 0.79 | 0.27 ± 0.71 |
| Week 5 (n = 89, 99) | 0.10 ± 0.81 | 0.13 ± 1.01 |
| Week 7 (n = 88, 97) | -0.22 ± 0.90 | -0.19 ± 1.42 |
| Week 9 (n = 89, 100) | -0.12 ± 0.93 | -0.28 ± 1.08 |
| Week 11 (n = 88, 99) | 0.02 ± 1.01 | 0.19 ± 0.67 |
| Week 13 (n = 89, 100) | -0.05 ± 0.93 | -0.19 ± 0.97 |
| Week 15 (n = 89, 100) | 0.19 ± 1.01 | -0.01 ± 0.87 |
| Week 17 (n = 89, 100) | -0.22 ± 1.08 | 0.02 ± 1.07 |
| Week 19 (n = 89, 100) | 0.18 ± 0.97 | -0.06 ± 1.25 |
| Week 21 (n = 87, 99) | -0.02 ± 0.74 | -0.06 ± 0.72 |
| Week 23 (n = 88, 98) | 0.16 ± 0.87 | 0.09 ± 0.78 |
| Week 25 (n = 87, 98) | 0.07 ± 0.78 | -0.06 ± 0.84 |
| Week 27 (n = 88, 94) | -0.18 ± 0.77 | 0.01 ± 0.85 |
| Week 29 (n =89, 92) | 0.04 ± 0.86 | 0.05 ± 0.73 |
| Week 31 (n = 85, 89) | -0.02 ± 0.72 | -0.03 ± 0.74 |
| Week 33 (n = 86, 90) | -0.16 ± 0.82 | 0.06 ± 0.74 |
| Week 35 (n = 87, 88) | -0.05 ± 0.98 | -0.13 ± 0.72 |
| Week 37 (n = 87, 93) | -0.04 ± 1.00 | -0.03 ± 0.64 |
Intra-subject variability was defined for each participant as the standard deviation (SD) of all of the hemoglobin concentrations during the evaluation period for the participant. The mean intra-subject SD for all participants is the sum of the intra-subject SDs divided by the total number of participants evaluated.
| g/dL | Epoetin Alfa Alternative Titration | Epoetin Alfa USPI Titration |
|---|---|---|
| Hemoglobin Intra-subject Variability | 0.74 ± 0.30 | 0.70 ± 0.32 |
An excursion is identified as an event when a hemoglobin concentration fell below or exceeded the pre-specified thresholds of: - \< 9.0 g/dL, or - \> 11.0 g/dL, or - \> 12.0 g/dL. The percentage of participants with any excursions and excursions in each subcategory at each time point and overall during the study are reported.
| percentage of participants | Epoetin Alfa Alternative Titration | Epoetin Alfa USPI Titration |
|---|---|---|
| Overall Excursions (n = 89, 100) | 91.0 | 93.0 |
| Overall Excursions < 9.0 (n = 89, 100) | 48.3 | 61.0 |
| Overall Excursions > 11.0 (n = 89, 100) | 80.9 | 83.0 |
| Overall Excursions > 12.0 (n = 89, 100) | 25.8 | 19.0 |
| Baseline Excursions (n = 89, 100) | 3.4 | 11.0 |
| Baseline Excursions < 9.0 (n = 89, 100) | 3.4 | 11.0 |
| Baseline Excursions > 11.0 (n = 89, 100) | 0.0 | 0.0 |
| Baseline Excursions > 12.0 (n = 89, 100) | 0.0 | 0.0 |
| Week 3 Excursions (n = 89, 100) | 29.2 | 27.0 |
| Week 3 Excursions < 9.0 (n = 89, 100) | 2.2 | 6.0 |
| Week 3 Excursions > 11.0 (n = 89, 100) | 27.0 | 21.0 |
| Week 3 Excursions > 12.0 (n = 89, 100) | 5.6 | 5.0 |
| Week 5 Excursions (n = 89, 99) | 36.0 | 29.3 |
| Week 5 Excursions < 9.0 (n = 89, 99) | 1.1 | 4.0 |
| Week 5 Excursions > 11.0 (n = 89, 99) | 34.8 | 25.3 |
| Week 5 Excursions > 12.0 (n = 89, 99) | 5.6 | 7.1 |
| Week 7 Excursions (n = 88, 97) | 27.3 | 28.9 |
| Week 7 Excursions < 9.0 (n = 88, 97) | 6.8 | 8.2 |
| Week 7 Excursions > 11.0 (n = 88, 97) | 20.5 | 20.6 |
| Week 7 Excursions > 12.0 (n = 88, 97) | 3.4 | 4.1 |
| Week 9 Excursions (n = 89, 100) | 29.2 | 17.0 |
| Week 9 Excursions < 9.0 (n = 89, 100) | 9.0 | 10.0 |
| Week 9 Excursions > 11.0 (n = 89, 100) | 20.2 | 7.0 |
| Week 9 Excursions > 12.0 (n = 89, 100) | 3.4 | 0.0 |
| Week 11 Excursions (n = 88, 99) | 22.7 | 23.2 |
| Week 11 Excursions < 9.0 (n = 88, 99) | 4.5 | 7.1 |
| Week 11 Excursions > 11.0 (n = 88, 99) | 18.2 | 16.2 |
| Week 11 Excursions > 12.0 (n = 88, 99) | 2.3 | 1.0 |
| Week 13 Excursions (n = 89, 100) | 25.8 | 21.0 |
| Week 13 Excursions < 9.0 (n = 89, 100) | 7.9 | 9.0 |
| Week 13 Excursions > 11.0 (n = 89, 100) | 18.0 | 12.0 |
| Week 13 Excursions > 12.0 (n = 89, 100) | 4.5 | 1.0 |
| Week 15 Excursions (n = 89, 100) | 27.0 | 24.0 |
| Week 15 Excursions < 9.0 (n = 89, 100) | 5.6 | 13.0 |
| Week 15 Excursions > 11.0 (n = 89, 100) | 21.3 | 11.0 |
| Week 15 Excursions > 12.0 (n = 89, 100) | 6.7 | 0.0 |
| Week 17 Excursions (n = 89, 100) | 23.6 | 21.0 |
| Week 17 Excursions < 9.0 (n = 89, 100) | 9.0 | 12.0 |
| Week 17 Excursions > 11.0 (n = 89, 100) | 14.6 | 9.0 |
| Week 17 Excursions > 12.0 (n = 89, 100) | 4.5 | 3.0 |
| Week 19 Excursions (n = 89, 100) | 28.1 | 19.0 |
| Week 19 Excursions < 9.0 (n = 89, 100) | 9.0 | 13.0 |
| Week 19 Excursions > 11.0 (n = 89, 100) | 19.1 | 6.0 |
| Week 19 Excursions > 12.0 (n = 89, 100) | 9.0 | 0.0 |
| Week 21 Excursions (n = 87, 99) | 27.6 | 17.2 |
| Week 21 Excursions < 9.0 (n = 87, 99) | 8.0 | 12.1 |
| Week 21 Excursions > 11.0 (n = 87, 99) | 19.5 | 5.1 |
| Week 21 Excursions > 12.0 (n = 87, 99) | 3.4 | 0.0 |
| Week 23 Excursions (n = 88, 98) | 29.5 | 20.4 |
| Week 23 Excursions < 9.0 (n = 88, 98) | 6.8 | 10.2 |
| Week 23 Excursions > 11.0 (n = 88, 98) | 22.7 | 10.2 |
| Week 23 Excursions > 12.0 (n = 88, 98) | 5.7 | 0.0 |
| Week 25 Excursions (n = 87, 98) | 28.7 | 20.4 |
| Week 25 Excursions < 9.0 (n = 87, 98) | 2.3 | 13.3 |
| Week 25 Excursions > 11.0 (n = 87, 98) | 26.4 | 7.1 |
| Week 25 Excursions > 12.0 (n = 87, 98) | 5.7 | 2.0 |
| Week 27 Excursions (n = 88, 94) | 29.5 | 21.3 |
| Week 27 Excursions < 9.0 (n = 88, 94) | 10.2 | 16.0 |
| Week 27 Excursions > 11.0 (n = 88, 94) | 19.3 | 5.3 |
| Week 27 Excursions > 12.0 (n = 88, 94) | 3.4 | 0.0 |
| Week 29 Excursions (n = 89, 92) | 25.8 | 29.3 |
| Week 29 Excursions < 9.0 (n = 89, 92) | 5.6 | 16.3 |
| Week 29 Excursions > 11.0 (n = 89, 92) | 20.2 | 13.0 |
| Week 29 Excursions > 12.0 (n = 89, 92) | 4.5 | 2.2 |
| Week 31 Excursions (n = 85, 89) | 20.0 | 28.1 |
| Week 31 Excursions < 9.0 (n = 85, 89) | 4.7 | 16.9 |
| Week 31 Excursions > 11.0 (n = 85, 89) | 15.3 | 11.2 |
| Week 31 Excursions > 12.0 (n = 85, 89) | 5.9 | 1.1 |
| Week 33 Excursions (n = 86, 90) | 22.1 | 22.2 |
| Week 33 Excursions < 9.0 (n = 86, 90) | 7.0 | 11.1 |
| Week 33 Excursions > 11.0 (n = 86, 90) | 15.1 | 11.1 |
| Week 33 Excursions > 12.0 (n = 86, 90) | 3.5 | 2.2 |
| Week 35 Excursions (n = 87, 88) | 26.4 | 21.6 |
| Week 35 Excursions < 9.0 (n = 87, 88) | 11.5 | 13.6 |
| Week 35 Excursions > 11.0 (n = 87, 88) | 14.9 | 8.0 |
| Week 35 Excursions > 12.0 (n = 87, 88) | 4.6 | 0.0 |
| Week 37 Excursions (n = 87, 93) | 20.7 | 17.2 |
| Week 37 Excursions < 9.0 (n = 87, 93) | 8.0 | 12.9 |
| Week 37 Excursions > 11.0 (n = 87, 93) | 12.6 | 4.3 |
| Week 37 Excursions > 12.0 (n = 87, 93) | 3.4 | 0.0 |
| units | Epoetin Alfa Alternative Titration | Epoetin Alfa USPI Titration |
|---|---|---|
| Week 1 (n = 89, 100) | 13139.9 ± 9360.1 | 10400 ± 8439.9 |
| Week 3 (n = 89, 100) | 9683.7 ± 9162.9 | 6912.5 ± 7459.4 |
| Week 5 (n = 89, 100) | 8324.2 ± 8689.7 | 6874.0 ± 8204.3 |
| Week 7 (n = 89, 100) | 9319.1 ± 7977.5 | 6411.0 ± 7040.6 |
| Week 9 (n = 89, 100) | 9253.4 ± 8536.9 | 8003.0 ± 7292.8 |
| Week 11 (n = 89, 100) | 10039.3 ± 9194.1 | 6483.0 ± 6854.9 |
| Week 13 (n = 89, 100) | 10358.4 ± 10247.7 | 7387.5 ± 7271.6 |
| Week 15 (n = 89, 100) | 8889.3 ± 8316.8 | 6874.5 ± 5952.9 |
| Week 17 (n = 89, 100) | 10251.7 ± 9973.7 | 6924.5 ± 6211.1 |
| Week 19 (n = 89, 100) | 10475.8 ± 10437.0 | 7112.5 ± 6300.4 |
| Week 21 (n = 89, 99) | 9605.1 ± 8225.0 | 6909.6 ± 6102.5 |
| Week 23 (n = 89, 98) | 8905.1 ± 7748.3 | 6830.1 ± 6397.0 |
| Week 25 (n = 89, 98) | 7543.8 ± 7225.1 | 7486.7 ± 6676.2 |
| Week 27 (n = 89, 96) | 9765.7 ± 12013.7 | 6662.5 ± 6362.8 |
| Week 29 (n =89, 94) | 9088.8 ± 10146.9 | 6083.0 ± 6149.1 |
| Week 31 (n = 88, 91) | 8543.2 ± 10821.7 | 6673.1 ± 6277.6 |
| Week 33 (n = 87, 90) | 9019.0 ± 10466.9 | 6235.6 ± 6041.6 |
| Week 35 (n = 87, 90) | 8709.2 ± 8631.9 | 5950.6 ± 5364.6 |
The number of red blood cell (RBC) units transfused during the study and during each study period.
| participants | Epoetin Alfa Alternative Titration | Epoetin Alfa USPI Titration |
|---|---|---|
| Overall Study: 1 RBC Unit (n = 89, 100) | 1 | 4 |
| Overall Study: 2 RBC Units (n = 89, 100) | 2 | 5 |
| Overall Study: 3 RBC Units (n = 89, 100) | 1 | 2 |
| Overall Study: > 3 RBC Units (n = 89, 100) | 2 | 1 |
| Titration Period: 1 RBC Unit (n = 89, 100) | 0 | 1 |
| Titration Period: 2 RBC Units (n = 89, 100) | 1 | 0 |
| Titration Period: 3 RBC Units (n = 89, 100) | 1 | 0 |
| Titration Period: > 3 RBC Units (n = 89, 100) | 0 | 0 |
| Evaluation Period: 1 RBC Unit (n = 89, 100) | 1 | 3 |
| Evaluation Period: 2 RBC Units (n = 89, 100) | 3 | 4 |
| Evaluation Period: 3 RBC Units (n = 89, 100) | 1 | 2 |
| Evaluation Period: > 3 RBC Units (n = 89, 100) | 0 | 1 |
| Safety Follow-up Period: 1 RBC Unit (n = 83, 90) | 0 | 0 |
| Safety Follow-up Period: 2 RBC Units (n = 83, 90) | 1 | 1 |
| Safety Follow-up Period: 3 RBC Units (n = 83, 90) | 0 | 0 |
| Safety Follow-up Period: >3 RBC Units (n = 83, 90) | 0 | 0 |
Collected over 41 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Epoetin Alfa Alternative Titration | — | 37/104 (35.6%) | 19/104 (18.3%) |
| Epoetin Alfa USPI Titration | — | 39/107 (36.4%) | 26/107 (24.3%) |
| Event | Epoetin Alfa Alternative Titration | Epoetin Alfa USPI Titration |
|---|---|---|
| Fluid overloadMetabolism and nutrition disorders | 3/104 | 9/107 |
| PneumoniaInfections and infestations | 2/104 | 6/107 |
| Cerebrovascular accidentNervous system disorders | 0/104 | 4/107 |
| Cardiac arrestCardiac disorders | 3/104 | 1/107 |
| Cardiac failure congestiveCardiac disorders | 3/104 | 2/107 |
| HyperkalaemiaMetabolism and nutrition disorders | 3/104 | 1/107 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 2/104 | 3/107 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/104 | 3/107 |
| Non-cardiac chest painGeneral disorders | 2/104 | 0/107 |
| Cholecystitis acuteHepatobiliary disorders | 2/104 | 0/107 |
| Event | Epoetin Alfa Alternative Titration | Epoetin Alfa USPI Titration |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 8/104 | 8/107 |
| HypertensionVascular disorders | 5/104 | 8/107 |
| AnaemiaBlood and lymphatic system disorders | 2/104 | 7/107 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 6/104 | 4/107 |
| Haemoglobin increasedInvestigations | 3/104 | 6/107 |
All randomized participants
| Age, Continuous(years) | Epoetin Alfa Alternative Titration | Epoetin Alfa USPI Titration | Total |
|---|---|---|---|
| Mean | 60.9 ± 13.3 | 58.7 ± 14.2 | 59.8 ± 1.8 |
| Sex: Female, Male(Participants) | Epoetin Alfa Alternative Titration | Epoetin Alfa USPI Titration | Total |
|---|---|---|---|
| Female | 48 | 40 | 88 |
| Male | 60 | 68 | 128 |
| Race/Ethnicity, Customized(participants) | Epoetin Alfa Alternative Titration | Epoetin Alfa USPI Titration | Total |
|---|---|---|---|
| Asian | 7 | 7 | 14 |
| Black | 53 | 50 | 103 |
| Native Hawaiian or other Pacific Islander | 0 | 1 | 1 |
| White | 40 | 40 | 80 |
| Other | 8 | 10 | 18 |
| Race/Ethnicity, Customized(participants) | Epoetin Alfa Alternative Titration | Epoetin Alfa USPI Titration | Total |
|---|---|---|---|
| Hispanic/Latino | 30 | 39 | 69 |
| Not Hispanic/Latino | 78 | 69 | 147 |
Ran from Apr 2015 to primary completion in Apr 2016, 12 months.
Results were first posted in May 2017, 1 year after primary completion.
Of 116 phase 4 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Epoetin Alfa
Renal Insufficiency, Chronic →